

# Nicola Ferri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1868106/publications.pdf>

Version: 2024-02-01

170  
papers

5,421  
citations

81900

39  
h-index

110387

64  
g-index

178  
all docs

178  
docs citations

178  
times ranked

7082  
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-lipid-related effects of statins. <i>Annals of Medicine</i> , 2000, 32, 164-176.	3.8	300
2	Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. <i>Atherosclerosis</i> , 2012, 220, 381-386.	0.8	212
3	Direct vascular effects of HMG-CoA reductase inhibitors. <i>Atherosclerosis</i> , 1998, 137, S101-S109.	0.8	193
4	PCSK9 induces a pro-inflammatory response in macrophages. <i>Scientific Reports</i> , 2018, 8, 2267.	3.3	166
5	Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity. , 2013, 138, 470-484.		161
6	Role of Discoidin Domain Receptors 1 and 2 in Human Smooth Muscle Cell-Mediated Collagen Remodeling. <i>American Journal of Pathology</i> , 2004, 164, 1575-1585.	3.8	158
7	Thematic Review Series: The Immune System and Atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. <i>Journal of Lipid Research</i> , 2005, 46, 1081-1092.	4.2	145
8	xIAP Induces Cell-Cycle Arrest and Activates Nuclear Factor- $\kappa$ B. <i>Circulation Research</i> , 2001, 88, 282-290.	4.5	131
9	Liver fat accumulation is associated with circulating PCSK9. <i>Annals of Medicine</i> , 2016, 48, 384-391.	3.8	119
10	Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties. <i>Drugs</i> , 2013, 73, 1681-1709.	10.9	118
11	Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. <i>Atherosclerosis</i> , 2017, 256, 1-6.	0.8	98
12	Virtual Screening Approach for the Identification of New Rac1 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4087-4090.	6.4	96
13	Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line. <i>Journal of Biological Chemistry</i> , 2016, 291, 3508-3519.	3.4	93
14	PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. <i>Atherosclerosis</i> , 2016, 253, 214-224.	0.8	78
15	Pharmacokinetics interactions of monoclonal antibodies. <i>Pharmacological Research</i> , 2016, 111, 592-599.	7.1	78
16	The dopamine D1 receptor agonists, A68930 and SKF 38393, induce arousal and suppress REM sleep in the rat. <i>European Journal of Pharmacology</i> , 1993, 235, 83-87.	3.5	66
17	Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	66
18	Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels “ experimental and clinical approaches with lipid-lowering agents. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 930-949.	1.8	64

#	ARTICLE	IF	CITATIONS
19	Proprotein Convertase Subtilisin/Kexin Type 9. American Journal of Pathology, 2021, 191, 1385-1397.	3.8	62
20	PCSK9 as a Positive Modulator of Platelet Activation. Journal of the American College of Cardiology, 2018, 71, 952-954.	2.8	60
21	Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia. Endocrine, 2016, 54, 588-601.	2.3	58
22	Disruption of ArhGAP15 results in hyperactive Rac1, affects the architecture and function of hippocampal inhibitory neurons and causes cognitive deficits. Scientific Reports, 2016, 6, 34877.	3.3	58
23	Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovascular Research, 2023, 118, 3288-3304.	3.8	57
24	Clinical approach to the inflammatory etiology of cardiovascular diseases. Pharmacological Research, 2020, 159, 104916.	7.1	56
25	Effects of repeated administration of selective adenosine A1 and A2A receptor agonists on pentylenetetrazole-induced convulsions in the rat. European Journal of Pharmacology, 1995, 294, 383-389.	3.5	55
26	Muscle cells and motoneurons differentially remove mutant SOD1 causing familial amyotrophic lateral sclerosis. Journal of Neurochemistry, 2011, 118, 266-280.	3.9	55
27	17-AAG increases autophagic removal of mutant androgen receptor in spinal and bulbar muscular atrophy. Neurobiology of Disease, 2011, 41, 83-95.	4.4	55
28	Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia. Pharmacological Research, 2020, 153, 104653.	7.1	54
29	The Glycolytic Enzyme PFKFB3 Is Involved in Estrogen-Mediated Angiogenesis via GPER1. Journal of Pharmacology and Experimental Therapeutics, 2017, 361, 398-407.	2.5	53
30	Everolimus Inhibits Monocyte/Macrophage Migration in Vitro and Their Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 419-425.	2.5	52
31	Dipeptide Nanotubes Containing Unnatural Fluorine-Substituted <sup>2,3</sup> -Diarylamino Acid and Alanine as Candidates for Biomedical Applications. Organic Letters, 2015, 17, 4468-4471.	4.6	50
32	Differential Processing of $\hat{1}\pm$ - and $\hat{2}$ -Defensin Precursors by Matrix Metalloproteinase-7 (MMP-7). Journal of Biological Chemistry, 2009, 284, 8301-8311.	3.4	49
33	Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 315-320.	2.6	47
34	Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. Translational Research, 2016, 173, 19-29.	5.0	45
35	Present therapeutic role of cholesteryl ester transfer protein inhibitors. Pharmacological Research, 2018, 128, 29-41.	7.1	45
36	PPAR- $\hat{1}\pm$ agonists are still on the rise: an update on clinical and experimental findings. Expert Opinion on Investigational Drugs, 2017, 26, 593-602.	4.1	44

#	ARTICLE	IF	CITATIONS
37	Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 120.	3.4	43
38	Naturally Occurring PCSK9 Inhibitors. <i>Nutrients</i> , 2020, 12, 1440.	4.1	43
39	Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2660-2669.	3.6	42
40	Tuning the cytotoxicity of ruthenium(ii) para-cymene complexes by mono-substitution at a triphenylphosphine/phenoxydiphenylphosphine ligand. <i>Dalton Transactions</i> , 2017, 46, 16589-16604.	3.3	42
41	The small heat shock protein B8 (HSPB8) modulates proliferation and migration of breast cancer cells. <i>Oncotarget</i> , 2017, 8, 10400-10415.	1.8	42
42	Efficient Expression of Exogenous Genes in Primary Vascular Cells Using IRES-Based Retroviral Vectors. <i>BioTechniques</i> , 2002, 32, 830-843.	1.8	41
43	Lipid Lowering Drugs: Present Status and Future Developments. <i>Current Atherosclerosis Reports</i> , 2021, 23, 17.	4.8	41
44	Integrin-Mediated Transcriptional Activation of Inhibitor of Apoptosis Proteins Protects Smooth Muscle Cells Against Apoptosis Induced by Degraded Collagen. <i>Circulation Research</i> , 2006, 98, 1490-1497.	4.5	39
45	Simvastatin Reduces MMP1 Expression in Human Smooth Muscle Cells Cultured on Polymerized Collagen by Inhibiting Rac1 Activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 1043-1049.	2.4	39
46	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 40-52.	3.1	39
47	Exploring the Anticancer Potential of Diiron Bis-cyclopentadienyl Complexes with Bridging Hydrocarbyl Ligands: Behavior in Aqueous Media and <i>In Vitro</i> Cytotoxicity. <i>Organometallics</i> , 2020, 39, 645-657.	2.3	38
48	Ajoene, a garlic compound, inhibits protein prenylation and arterial smooth muscle cell proliferation. <i>British Journal of Pharmacology</i> , 2003, 138, 811-818.	5.4	37
49	An <i>in Vivo</i> active 1,2,5-oxadiazole Pt(II) complex: A promising anticancer agent endowed with STAT3 inhibitory properties. <i>European Journal of Medicinal Chemistry</i> , 2017, 131, 196-206.	5.5	37
50	Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells. <i>Atherosclerosis</i> , 2011, 214, 331-337.	0.8	36
51	Angiopietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects. <i>Journal of Cardiovascular Development and Disease</i> , 2018, 5, 39.	1.6	36
52	Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 578-588.	1.8	36
53	Fas and Fas-Associated Death Domain Protein Regulate Monocyte Chemoattractant Protein-1 Expression by Human Smooth Muscle Cells Through Caspase- and Calpain-Dependent Release of Interleukin-1 $\beta$ . <i>Circulation Research</i> , 2003, 93, 515-522.	4.5	35
54	Human megakaryocytes confer tissue factor to a subset of shed platelets to stimulate thrombin generation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 579-592.	3.4	34

#	ARTICLE	IF	CITATIONS
55	PCSK9 Involvement in Aortic Valve Calcification. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3225-3227.	2.8	34
56	An NF- $\kappa$ B-dependent Transcriptional Program Is Required for Collagen Remodeling by Human Smooth Muscle Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 19757-19764.	3.4	33
57	2-Amino-3-(phenylsulfanyl)norborene-2-carboxylate: An Appealing Scaffold for the Design of Rac1-Targeted Protein-Protein Interaction Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2953-2962.	6.4	31
58	Depression and cardiovascular risk association among Beck Depression Inventory, PCSK9 levels and insulin resistance. <i>Cardiovascular Diabetology</i> , 2020, 19, 187.	6.8	31
59	Clinical Pharmacology of Statins: an Update. <i>Current Atherosclerosis Reports</i> , 2020, 22, 26.	4.8	31
60	Role of Small GTPase Protein Rac1 in Cardiovascular Diseases. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 62, 425-435.	1.9	30
61	Lipid-modified proteins as biomarkers for cardiovascular disease: a review. <i>Biomarkers</i> , 2005, 10, 219-237.	1.9	29
62	In vitro anticancer activity evaluation of new cationic platinum(II) complexes based on imidazole moiety. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 1907-1913.	3.0	29
63	Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study. <i>Atherosclerosis</i> , 2020, 309, 39-46.	0.8	29
64	Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice. <i>Pharmaceutics</i> , 2022, 14, 1120.	4.5	29
65	Aliskiren reduces prorenin receptor expression and activity in cultured human aortic smooth muscle cells. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2011, 12, 469-474.	1.7	28
66	Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. <i>Annals of Medicine</i> , 2018, 50, 461-484.	3.8	28
67	Chemotactic effect of prorenin on human aortic smooth muscle cells: a novel function of the (pro)renin receptor. <i>Cardiovascular Research</i> , 2012, 95, 366-374.	3.8	27
68	Beyond the Endothelium. <i>Circulation Research</i> , 2004, 94, 706-708.	4.5	26
69	Biomarkers for atherosclerosis: pathophysiological role and pharmacological modulation. <i>Current Opinion in Lipidology</i> , 2006, 17, 495-501.	2.7	26
70	3-Aryl-N-aminoylsulfonylphenyl-1H-pyrazole-5-carboxamides: a new class of selective Rac inhibitors. <i>MedChemComm</i> , 2013, 4, 537.	3.4	26
71	Naturally occurring PDGF receptor inhibitors with potential anti-atherosclerotic properties. <i>Vascular Pharmacology</i> , 2015, 70, 1-7.	2.1	26
72	Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9. <i>American Journal of Pathology</i> , 2020, 190, 2226-2236.	3.8	26

#	ARTICLE	IF	CITATIONS
73	Cleavage of Focal Adhesion Kinase in Vascular Smooth Muscle Cells Overexpressing Membrane-Type Matrix Metalloproteinases. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 839-844.	2.4	25
74	Synthesis, structural, and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 5291-5299.	3.0	24
75	Current Evidence and Future Perspectives on Pharmacological Treatment of Calcific Aortic Valve Stenosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8263.	4.1	24
76	Antiproliferative effects on human tumor cells and rat aortic smooth muscular cells of 2,3-heteroarylmaleimides and heterofused imides. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 1691-1701.	3.0	23
77	Upregulation of lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human endothelial cells by modified high density lipoproteins. <i>Biochemical and Biophysical Research Communications</i> , 2012, 428, 230-233.	2.1	23
78	Cytotoxic effect of (1-methyl-1 H -imidazol-2-yl)-methanamine and its derivatives in Pt II complexes on human carcinoma cell lines: A comparative study with cisplatin. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 2379-2386.	3.0	23
79	Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. <i>Drugs</i> , 2020, 80, 1065-1083.	10.9	22
80	Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. <i>Thrombosis and Haemostasis</i> , 2015, 114, 186-197.	3.4	21
81	Promising antiproliferative platinum(II) complexes based on imidazole moiety: synthesis, evaluation in HCT-116 cancer cell line and interaction with Ctr-1 Met-rich domain. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 2538-2547.	3.0	21
82	Peptide modulators of Rac1/Tiam1 protein-protein interaction: An alternative approach for cardiovascular diseases. <i>Peptide Science</i> , 2018, 110, e23089.	1.8	21
83	Himalayan Nettle <i>Cirardinia diversifolia</i> as a Candidate Ingredient for Pharmaceutical and Nutraceutical Applications—Phytochemical Analysis and In Vitro Bioassays. <i>Molecules</i> , 2020, 25, 1563.	3.8	21
84	Are pleiotropic effects of statins real?. <i>Vascular Health and Risk Management</i> , 2007, 3, 611-3.	2.3	21
85	Peptidomimetic inhibitors of farnesyltransferase with high in vitro activity and significant cellular potency. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 6192-6196.	2.2	20
86	Synthetic peptides containing a conserved sequence motif of the Id protein family modulate vascular smooth muscle cell phenotype. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6298-6302.	2.2	20
87	Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 5408-5412.	2.2	20
88	AMP-activated protein kinase and the control of smooth muscle cell hyperproliferation in vascular disease. <i>Vascular Pharmacology</i> , 2012, 56, 9-13.	2.1	20
89	Clinical evidence of statin therapy in non-dyslipidemic disorders. <i>Pharmacological Research</i> , 2014, 88, 20-30.	7.1	20
90	Bococizumab for the treatment of hypercholesterolaemia. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 237-243.	3.1	20

#	ARTICLE	IF	CITATIONS
91	Lipoprotein(a) and PCSK9 inhibition: clinical evidence. <i>European Heart Journal Supplements</i> , 2020, 22, L53-L56.	0.1	20
92	From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1843-1851.	1.8	19
93	PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3134.	2.4	19
94	Fucus vesiculosus and Ascophyllum nodosum Ameliorate Liver Function by Reducing Diet-Induced Steatosis in Rats. <i>Marine Drugs</i> , 2020, 18, 62.	4.6	19
95	<a href="#">Effect of S(âˆ-) perillic acid on protein prenylation and arterial smooth muscle cell proliferation</a> †2â† This research was partially supported by Institut of Recherches Internationales Servier, Paris, France. N. Ferri, L. Arnaboldi, and A. Corsini are also partially supported by a grant from the Ministero		

#	ARTICLE	IF	CITATIONS
109	Cross-talk between EGFR and T-cadherin: EGFR activation promotes T-cadherin localization to intercellular contacts. <i>Cellular Signalling</i> , 2013, 25, 1044-1053.	3.6	12
110	Angiotensin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 2251-2254.	1.8	12
111	Cytotoxic performances of new anionic cyclometalated Pt(II) complexes bearing chelated O <sup>2-</sup> ligands. <i>Applied Organometallic Chemistry</i> , 2020, 34, e5455.	3.5	12
112	A field-based disparity analysis of new 1,2,5-triazole derivatives endowed with antiproliferative activity. <i>Chemical Biology and Drug Design</i> , 2017, 90, 820-839.	3.2	11
113	Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: Role of the small G protein Rac1. <i>Pharmacological Research</i> , 2017, 122, 96-104.	7.1	11
114	The Brown Algae <i>Fucus vesiculosus</i> and <i>Ascophyllum nodosum</i> Reduce Metabolic Syndrome Risk Factors: A Clinical Study. <i>Natural Product Communications</i> , 2018, 13, 1934578X1801301.	0.5	11
115	Cholesterol-Lowering Action of a Novel Nutraceutical Combination in Uremic Rats: Insights into the Molecular Mechanism in a Hepatoma Cell Line. <i>Nutrients</i> , 2020, 12, 436.	4.1	11
116	Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases. <i>Scientifica</i> , 2012, 2012, 1-21.	1.7	10
117	Nitric Oxide-Donating Atorvastatin Attenuates Neutrophil Recruitment During Vascular Inflammation Independent of Changes in Plasma Cholesterol. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 211-219.	2.6	9
118	Off-label use of reduced dose direct oral factor Xa inhibitors in subjects with atrial fibrillation: a review of clinical evidence. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 334-345.	3.0	9
119	Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies. <i>European Heart Journal Supplements</i> , 2020, 22, E64-E67.	0.1	9
120	Development of poly(lactide-co-glycolide) nanoparticles functionalized with a mitochondria penetrating peptide. <i>Journal of Peptide Science</i> , 2017, 23, 182-188.	1.4	9
121	Impact of Soy Î²-Conglycinin Peptides on PCSK9 Protein Expression in HepG2 Cells. <i>Nutrients</i> , 2022, 14, 193.	4.1	9
122	Methanethiosulfonate derivatives as ligands of the STAT3-SH2 domain. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2017, 32, 337-344.	5.2	8
123	New sulfurated derivatives of cinnamic acids and rosmarinic acid as inhibitors of STAT3 and NF-Î²B transcription factors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2017, 32, 1012-1028.	5.2	8
124	Proteolysis Targeting Chimeric Molecules: Tuning Molecular Strategies for a Clinically Sound Listening. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6630.	4.1	8
125	Isothiazole dioxide derivative 6n inhibits vascular smooth muscle cell proliferation and protein farnesylation. <i>Biochemical Pharmacology</i> , 2005, 70, 1735-1743.	4.4	7
126	Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosisâ€”The IMPROVE Study. <i>Biomedicines</i> , 2021, 9, 841.	3.2	6



#	ARTICLE	IF	CITATIONS
127	Impact of bariatric surgery-induced weight loss on circulating PCSK9 levels in obese patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 2372-2378.	2.6	5
128	Evaluation of the effects of natural isoquinoline alkaloids on low density lipoprotein receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) in hepatocytes, as new potential hypocholesterolemic agents. <i>Bioorganic Chemistry</i> , 2022, 121, 105686.	4.1	5
129	Inhibition of Smooth Muscle Cell Migration and Proliferation by Statins. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2008, 8, 122-140.	0.5	4
130	Aliskiren inhibits prorenin-induced human aortic smooth muscle cell migration. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 284-291.	1.7	4
131	Identification of the first enantiopure Rac1 protein interaction inhibitor and its optimized synthesis via phosphine free remote group directed hydroarylation. <i>MedChemComm</i> , 2019, 10, 310-314.	3.4	4
132	PCSK9 Induces Rat Smooth Muscle Cell Proliferation and Counteracts the Pleiotropic Effects of Simvastatin. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4114.	4.1	4
133	The Emerging Role of Nutraceuticals in Cardiovascular Calcification: Evidence from Preclinical and Clinical Studies. <i>Nutrients</i> , 2021, 13, 2603.	4.1	4
134	The Modulation of PCSK9 and LDLR by Supercritical CO <sub>2</sub> Extracts of <i>Mentha longifolia</i> and Isolated Piperitone Oxide, an In Vitro Study. <i>Molecules</i> , 2021, 26, 3886.	3.8	2
135	Synthesis of new dithiolethione and methanethiosulfonate systems endowed with pharmaceutical interest. <i>Arkivoc</i> , 2017, 2017, 235-250.	0.5	2
136	Nutrition Intervention and Cardiovascular Disease. <i>Nutrients</i> , 2022, 14, 1435.	4.1	2
137	NMR, LC-MS Characterization of <i>Rydingia michauxii</i> Extracts, Identification of Natural Products Acting as Modulators of LDLR and PCSK9. <i>Molecules</i> , 2022, 27, 2256.	3.8	2
138	Fibrillar Collagen Inhibits Cholesterol Biosynthesis in Human Aortic Smooth Muscle Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1631-1637.	2.4	1
139	Pharmacological Modulation of Small GTPases in Cardiovascular Diseases. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 62, 329-330.	1.9	1
140	TNF-alpha induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line in a SOCS-3-dependent manner. <i>Atherosclerosis</i> , 2016, 252, e197-e198.	0.8	1
141	A new role for PCSK9 as a co-activator of platelet reactivity. <i>Atherosclerosis</i> , 2017, 263, e29.	0.8	1
142	Phage display for targeting PCSK9. <i>EBioMedicine</i> , 2021, 65, 103267.	6.1	1
143	The Metabolic Activation of Sofosbuvir Is Impaired in an Experimental Model of NAFLD. <i>Biology</i> , 2022, 11, 693.	2.8	1
144	3.P.247 Farnesol and geranylgeraniol prevent the inhibition elicited by simvastatin on proliferation and actin polymerization in rat arterial smooth muscle cells. <i>Atherosclerosis</i> , 1997, 134, 250.	0.8	0

#	ARTICLE	IF	CITATIONS
145	3.P.244 L(α <sup>+</sup> ) perillic acid inhibits protein prenylation and the growth of rat and human arterial myocytes <i>in vitro</i> . <i>Atherosclerosis</i> , 1997, 134, 249.	0.8	0
146	3.P.239 Pharmacological control of protein prenylation and arterial smooth muscle cell proliferation. <i>Atherosclerosis</i> , 1997, 134, 248.	0.8	0
147	1.P.172 Antiatherosclerotic activities of mibefradil in cell culture models. <i>Atherosclerosis</i> , 1997, 134, 53.	0.8	0
148	C24 Inhibitory effect of L(α <sup>+</sup> )perillic acid on protein prenylation and myocyte proliferation. <i>Atherosclerosis</i> , 1999, 145, S6.	0.8	0
149	Tu-W18:6 Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting RAC1 activation. <i>Atherosclerosis Supplements</i> , 2006, 7, 157.	1.2	0
150	Tu-P7:271 Selective inhibition on gelatinase A and B versus collagenase-1 by an amino-sulphone-hydroxamate derivative. <i>Atherosclerosis Supplements</i> , 2006, 7, 244.	1.2	0
151	PO9-218 IN VITRO AND IN VIVO STUDIES OF ANTIATHEROSCLEROTIC PROPERTIES OF EVEROLIMUS. <i>Atherosclerosis Supplements</i> , 2007, 8, 71.	1.2	0
152	Proprotein convertase subtilisin/kexin type 9 deficient mice are protected from neointima formation in carotid artery injury model. <i>Atherosclerosis</i> , 2014, 235, e21-e22.	0.8	0
153	The absence of the EDA alternative spliced isoform of fibronectin promotes smooth muscle cells migration and results in neo-intimal hyperplasia. <i>Atherosclerosis</i> , 2015, 241, e45.	0.8	0
154	STAT3 inhibition induces PCSK9 in hepatic cell line: possible involvement in hypertriglyceridemia associated with insulin resistance. <i>Atherosclerosis</i> , 2015, 241, e46-e47.	0.8	0
155	Liver fat accumulation is associated with circulating PCSK9 levels. <i>Digestive and Liver Disease</i> , 2015, 47, e230.	0.9	0
156	Smooth muscle cells PCSK9 knock-out exhibit an impaired response to PDGF stimulation. <i>Atherosclerosis</i> , 2016, 252, e200.	0.8	0
157	The absence of PCSK9 determines a lower neointimal formation in response to perivascular carotid collar placement. <i>Atherosclerosis</i> , 2016, 252, e233-e234.	0.8	0
158	In vitro evidence of a pro-inflammatory action of PCSK9 in THP-1-derived macrophages. <i>Atherosclerosis</i> , 2016, 252, e220.	0.8	0
159	Circulating PCSK9 Levels are Associated with the Hepatic Fat in Non-Alcoholic Fatty Liver Disease. <i>Journal of Hepatology</i> , 2016, 64, S492.	3.7	0
160	Influence of PCSK9 on biological behavior of mouse smooth muscle cells. <i>Atherosclerosis</i> , 2017, 263, e63.	0.8	0
161	Circulating levels of PCSK9 and arterial stiffness in a large population sample: Data from the brisighella heart study. <i>Atherosclerosis</i> , 2017, 263, e105-e106.	0.8	0
162	Leptin and resistin affect PCSK9 expression via STAT3 involvement. <i>Atherosclerosis</i> , 2017, 263, e70-e71.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Plasma PCSK9 levels and lipoprotein distribution are preserved in patients with severe hypoalphalipoproteinemia. <i>Atherosclerosis</i> , 2017, 263, e91.	0.8	0
164	PCSK9 induces a pro-inflammatory response in macrophages. <i>Atherosclerosis</i> , 2017, 263, e11.	0.8	0
165	Leaf extract of morus alba reduces the expression of proprotein convertase subtilisin kexin type 9 (PCSK9) in HEPG2 cell line. <i>Atherosclerosis</i> , 2018, 275, e55.	0.8	0
166	Leptin and resistin affect PCSK9 expression: In vitro and in vivo evidence. <i>Atherosclerosis</i> , 2018, 275, e18.	0.8	0
167	Drug-Drug Interaction with DOACs. , 2021, , 41-69.		0
168	Role of Isoprenoids In the Growth-Factor Signal Transduction and their Pharmacological Modulation. <i>Medical Science Symposia Series</i> , 1996, , 103-110.	0.0	0
169	Effect of Statins Beyond Lowering Cholesterol: Where Do We Stand?. <i>Medical Science Symposia Series</i> , 1998, , 253-265.	0.0	0
170	Effect of REL-1017 (Esmethadone) on Cholesterol, Triglycerides, PCSK9, and hs-CRP in a Phase 2a Double-Blind Randomized Trial in Patients with MDD. <i>CNS Spectrums</i> , 2022, 27, 246-247.	1.2	0